Lacosamid Stada (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons. By stabilising hyper‑excitable neuronal membranes, it reduces repetitive firing and limits the spread of epileptic discharges, thereby decreasing seizure activity without affecting normal rapid sodium channel function.

The dose of Lacosamid Stada is individualized by the prescribing clinician based on the patient’s age, weight, renal and hepatic function, and response to therapy. No fixed regimen is provided here; the prescriber sets the appropriate dosage and titration schedule.

Lacosamide is classified as Pregnancy Category C, indicating that risk to the fetus cannot be ruled out. It should only be used during pregnancy if the potential benefit justifies the risk. Limited data are available for breastfeeding; a decision should be made in consultation with a healthcare professional.

To order Lacosamid Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many antiepileptics that block fast sodium channels or modulate GABA. This can provide complementary seizure control when combined with other agents, and it may have a distinct side‑effect profile, often with lower cognitive impact compared with some older drugs.

Lacosamid Stada should be stored at ambient temperature below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and avoid storing them in bathrooms or near heat sources to maintain product stability.

Lacosamid Stada is taken orally, usually as a tablet swallowed whole with water. The exact dosing schedule—such as once or twice daily—and any titration steps are determined by the prescribing physician based on the individual’s clinical response.

Serious risks include the potential for suicidal thoughts or behavior, severe skin reactions like Stevens‑Johnson syndrome, and cardiac conduction abnormalities such as PR‑interval prolongation. Patients should be monitored for mood changes, skin eruptions, and any signs of cardiac issues, especially when initiating therapy.

Lacosamide should be avoided in patients with known hypersensitivity to the drug or any of its excipients. Caution is also advised for individuals with significant cardiac conduction disorders, severe renal or hepatic impairment, and those taking interacting medications that could markedly reduce its effectiveness.